Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
RESEARCH TOOLSreports
KalVista Pharmaceuticals (KALV) Stock Price & Analysis
357 Followers
KALV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.21 - $16.88
Previous Close$14.55
Volume203.19K
Average Volume (3M)345.49K
Market Cap
$621.80M
Enterprise Value$418.72M
Total Cash (Recent Filing)$210.40M
Total Debt (Recent Filing)$7.32M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Sep 05, 2024EPS Estimate
-$0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.40
Shares Outstanding42,188,296
10 Day Avg. Volume281,588
30 Day Avg. Volume345,491
Standard Deviation0.26
R-Squared0.03
Alpha0.00950
Financial Highlights & Ratios
Price to Book (P/B)5.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.22
Forecast
1Y Price Target
$29.20Price Target Upside100.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
KalVista Pharmaceuticals News
PremiumPre-Earnings
Is KALV a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Approval And Market PositionSebetralstat, if approved, would be the first oral on-demand therapy for the treatment of HAE.
Efficacy And ConvenienceSebetralstat could be the first oral option for on-demand attacks, combined with the compelling efficacy profile.
Market PotentialSebetralstat targets a $900MM market opportunity.
Bears Say
Market CompetitionBetween the growing prophylaxis market and the increased competition in the on-demand therapy space, it will be an uphill battle to capture meaningful market share.
Strategic ReviewFollowing a strategic review of the Factor XIIa program, the company determined that the most promising indications for development lie outside the company's core capabilities.
Treatment DemandAs the prophylactic treatment landscape continues to expand and improve, patients' disease burden will lessen resulting in a reduced need for on-demand HAE therapy.
---
Ownership Overview
72.67% Insiders
10.67% Mutual Funds
9.89% Other Institutional Investors
6.77% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $7.21 and its highest was $16.88 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
Currently, no data Available
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Sep 05, 2024 which is in 46 days.
How were KalVista Pharmaceuticals’s earnings last quarter?
KalVista Pharmaceuticals released its earnings results on Jul 11, 2024. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$0.713 by -$0.307.
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate is -$0.9.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 42,735,645 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
KalVista Pharmaceuticals reported an EPS of -$1.02 in its last earnings report, missing expectations of -$0.713. Following the earnings report the stock price went down -0.557%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Among the largest hedge funds holding KalVista Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds KalVista Pharmaceuticals’s shares valued at 6M.
---
KalVista Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.20 (100.69% Upside)
$29.20 (100.69% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 160.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 14.3%
Last 30 Days ▲ 14.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.07%
12-Months-Change
Fundamentals
Return on Equity
-68.90%
Trailing 12-Months
Asset Growth
28.49%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
---
KALV Stock 12 Month Forecast
Average Price Target
$29.20
▲(100.69% Upside)
Technical Analysis
Best Analysts Covering KALV
1 Year
1 Year Success Rate
14/20 ratings generated profit
1 Year Average Return
+20.91%
reiterated a buy rating 11 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +20.91% per trade.
---